A 12-Week Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Topiramate for the Treatment of Compulsive Buying Disorder

Nenhuma Miniatura disponível
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2020
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
KIM, Hyoun S.
Citação
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, v.40, n.2, p.186-190, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Topiramate is an anticonvulsant that has shown promise as a pharmacological agent for the treatment of addictive disorders, including compulsive buying disorder (CBD). The aim of the present study was to examine the efficacy of topiramate in the treatment of CBD and its associated characteristics using a 12-week randomized, double-blind, placebo-controlled design. Methods Fifty patients seeking treatment of CBD who met the inclusion criteria were randomly assigned to either the experimental group (n = 25) or the control group (n = 25). Both groups received 4 sessions of psychoeducation. Results Forty-four participants completed the follow-up with no differences in the rate of dropout between groups. There were no differences between participants who received topiramate or placebo in reducing CBD symptoms assessed by the primary outcome scale (Yale-Brown Obsessive-Compulsive Scale - Shopping Version). However, participants who received topiramate were significantly more likely to show clinical improvement when assessed by a secondary outcome measure, the Compulsive Buying Follow-Up Scale. In addition, there was a trend among participants who received topiramate to report improvements in aspects of hoarding and impulsivity compared with the control group. There were significant improvements in comorbid depression and social adjustments over time, but no group x time interaction was found. Conclusions The results do not provide support for the use of topiramate in the treatment of CBD. Future investigation with larger and representative samples and longer follow-up period are needed.
Palavras-chave
compulsive buying disorder, clinical trial, double blind, placebo controlled, topiramate
URI
https://observatorio.fm.usp.br/handle/OPI/36054
Referências
  1. Amorim Patricia, 2000, Revista Brasileira de Psiquiatria, V22, P106
  2. BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5
  3. Berlin HA, 2013, WORLD J BIOL PSYCHIA, V14, P121, DOI 10.3109/15622975.2011.560964
  4. Black DW, 2001, CNS DRUGS, V15, P17, DOI 10.2165/00023210-200115010-00003
  5. Bullock K, 2003, DRUG TODAY, V39, P695, DOI 10.1358/dot.2003.39.9.799477
  6. de Brito AMC, 2017, J GAMBL STUD, V33, P249, DOI 10.1007/s10899-016-9620-z
  7. Chow S, 2008, SAMPLE SIZE CALCULAT, P89
  8. Claudino AM, 2007, J CLIN PSYCHIAT, V68, P1324, DOI 10.4088/JCP.v68n0901
  9. David V, 1998, EUR J NEUROSCI, V10, P1394, DOI 10.1046/j.1460-9568.1998.00150.x
  10. de Mattos CN, 2019, PSYCHIAT RES, V282, DOI 10.1016/j.psychres.2018.12.078
  11. Filomensky TZ, 2012, COMPR PSYCHIAT, V53, P554, DOI 10.1016/j.comppsych.2011.09.005
  12. First M, 1997, STRUCTURED CLIN INTE
  13. Fontenelle IS, 2010, PSYCHOL REP, V106, P279, DOI 10.2466/PR0.106.1.279-296
  14. Gorenstein C, 2002, J AFFECT DISORDERS, V69, P167, DOI 10.1016/S0165-0327(01)00300-7
  15. Grant JE, 2016, JAMA PSYCHIAT, V73, P490, DOI 10.1001/jamapsychiatry.2016.0060
  16. Guy W, 1976, ECDEU ASSESSMENT MAN, P76
  17. Hague B, 2016, J BEHAV ADDICT, V5, P379, DOI 10.1556/2006.5.2016.064
  18. Johnson BA, 2003, LANCET, V361, P1677, DOI 10.1016/S0140-6736(03)13370-3
  19. Johnson BA, 2013, ADDICT BIOL, V18, P405, DOI 10.1111/j.1369-1600.2012.00499.x
  20. Leite PL, 2014, COMPR PSYCHIAT, V55, P1462, DOI 10.1016/j.comppsych.2014.04.012
  21. Leite Priscilla Lourenço, 2011, J. bras. psiquiatr., V60, P176, DOI 10.1590/S0047-20852011000300005
  22. Lingjaerde O, 1987, Acta Psychiatr Scand Suppl, V334, P1
  23. Malloy-Diniz LF, 2015, REV BRAS PSIQUIATR, V37, P245, DOI 10.1590/1516-4446-2014-1599
  24. Mitchell JE, 2006, BEHAV RES THER, V44, P1859, DOI 10.1016/j.brat.2005.12.009
  25. Mueller A, 2007, BEHAV RES THER, V45, P2754, DOI 10.1016/j.brat.2007.07.012
  26. Porter Roger J, 2012, Handb Clin Neurol, V108, P663, DOI 10.1016/B978-0-444-52899-5.00021-6
  27. Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi
  28. Soares C, 2016, CNS DRUGS, V30, P281, DOI 10.1007/s40263-016-0324-9
  29. Toledo EL, 2015, J CLIN PSYCHIAT, V76, P447, DOI 10.4088/JCP.13m08964
  30. World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/23